Name: Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), and Region - Global Forecast to 2030
Brand: MarketsandMarkets
SKU: MD3264
Price: 4950 USD
Availability: InStock

報告摘要

The global smart pills market is experiencing significant growth in 2024, driven by the technological advancements in capsule endoscopy and the growing demand for non-invasive diagnostic monitoring devices. The market is projected to reach reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period. According to the American Cancer Society (ACS), in 2024, there were 1,52,810 new cases of colorectal cancer (CRC) comprising, 81,540 will be in men and 71,270 in women. Additionally, 1,06,590 of the cases will be colon cancer, while 46,220 will be rectal cancer. CRC remains the second leading cause of cancer-related deaths in the US with an estimated 53,010 deaths in 2024, showing a slight increase from last year’s projected 52,550. Thus, the high incidence of colon cancer are expected to increase the demand for capsule endoscopes for colon cancer screening. “The small bowel tumor segment is projected to grow at the highest CAGR during the forecast period.” Based on disease indication, the market for smart pills is divided into segments for crohn’s disease, small bowel tumors, occult GI bleeding, celiac disease, and other disease indications. The small bowel tumor is expected to grow at the highest CAGR during the forecast period due to factors, such as advancements in sensor technology, growing emphasis on patient convenience, rising need for early tumor diagnosis and proper treatment that are expected to drive the adoption of smart pills in the coming years. “The large intestine accounted for the second largest share of the market during the forecast period in 2023, by target area. “ By target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. In 2023, the large intestine target area accounted for the second largest share of smart pills market. Factors such as rising cases of colorectal cancer and requirement for applicable screening, diagnosis, and examining of inflammatory bowel diseases and other gastrointestinal diseases. The growing cases of colorectal cancer & colon cancer have contributed to the rising adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be difficult to visualize with traditional methods. By region, Europe hold the second largest share of the smart pills market in 2023 Europe accounted for the second largest share of the smart pills market in 2023. Factors such as increase in ageing population and improved utilization of capsule endoscopy for gastrointestinal (GI) bleeding are driving the European smart pills market. According to the guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), small-bowel video capsule endoscopy is recommended as the initial examination for patients with unclear gastrointestinal bleeding. The endorsement of capsule endoscopy by the ESGE guidelines specifies a uniform approach for healthcare professionals, improving the quality of care provided to patients. As a result, the expanding demand for smart pills and other related technologies is driven by the growing use of capsule endoscopy for GI bleeding. The break up of the profile of primary participants in the smart pills market: • By Company Type: Tier 1- 40%, Tier 2- 35%, and Tier 25% • By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%. • By Region: North America- 45%, Europe- 30%, Asia Pacific- 20%, Latin America- 3%, and Middle East & Africa- 2%. Key players in the Smart pills market The key players operating in the smart pills market include Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) ,and Shangxian Minimal Invasive Inc (China). Research Coverage: The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application (capsule endoscopy,patient monitoring, and targeted drug delivery), target area (small intestine,large intestine, esophagus & stomach), disease indication (crohn’s disease, occult GI bleeding, small bowel tumor, celiac disease, & other disease conditions), end user (hospitals, diagnostic centers, outpatient settings, & other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies. Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market. This report provides insights into the following pointers: • Analysis of key drivers (rising demand for noninvasive diagnostic monitoring devices, technological advancements in capsule endoscopy, increasing incidence of colon cancer), restraints (high costs & technical limitations associated with accuracy of smart pills), opportunities (continuous innovation in sensor technology, wireless communication and rising need for rapid drug delivery development) and challenges (patient privacy concerns, shortage of skilled personnel). • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the smart pills market • Market Development: Comprehensive information about lucrative markets – the report analyses the smart pills market across varied regions. • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the smart pills market • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) , and Shangxian Minimal Invasive Inc (China) in the smart pills market.

目錄 Table of Contents

1 INTRODUCTION 25 1.1 STUDY OBJECTIVES 25 1.2 MARKET DEFINITION 25 1.3 STUDY SCOPE 26 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 26 1.3.2 INCLUSIONS & EXCLUSIONS 27 1.3.3 YEARS CONSIDERED 28 1.3.4 CURRENCY CONSIDERED 28 1.4 STAKEHOLDERS 28 1.5 SUMMARY OF CHANGES 29 2 RESEARCH METHODOLOGY 30 2.1 RESEARCH DATA 30 2.1.1 SECONDARY DATA 30 2.1.1.1 Key sources of secondary data 31 2.1.1.2 Key data from secondary sources 31 2.1.2 PRIMARY DATA 32 2.1.2.1 Objectives of primary research 32 2.1.2.2 Key data from primary sources 33 2.1.2.3 Insights from primary experts 33 2.1.3 MARKET SIZE ESTIMATION 34 2.1.3.1 Supply-side analysis 34 2.1.3.2 Bottom-up approach (demand-side analysis) 35 2.1.3.3 Top-down approach (parent market assessment) 36 2.2 DATA TRIANGULATION 40 2.3 STUDY ASSUMPTIONS 41 2.4 RISK ANALYSIS 41 2.5 RESEARCH LIMITATIONS 42 2.5.1 METHODOLOGY-RELATED LIMITATIONS 42 2.5.2 SCOPE-RELATED LIMITATIONS 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 47 4.1 SMART PILLS MARKET OVERVIEW 47 4.2 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023 48 4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 4.4 SMART PILLS MARKET: REGIONAL MIX 49 4.5 SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS 50 5 MARKET OVERVIEW 51 5.1 INTRODUCTION 51 5.2 MARKET DYNAMICS 51 5.2.1 DRIVERS 52 5.2.1.1 Rising demand for non-invasive diagnostic monitoring devices 52 5.2.1.2 Technological advancements in capsule endoscopy 53 5.2.1.3 Increasing incidence of colon cancer 54 5.2.2 RESTRAINTS 54 5.2.2.1 High R&D costs for technological developments and advancements 54 5.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills 55 5.2.3 OPPORTUNITIES 55 5.2.3.1 Innovations in sensor technologies and wireless communication 55 5.2.3.2 Rising need for rapid drug delivery and development 55 5.2.4 CHALLENGES 56 5.2.4.1 Increased patient privacy and data security concerns 56 5.2.4.2 Shortage of skilled healthcare professionals 57 5.3 INDUSTRY TRENDS 58 5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES 58 5.3.2 INTEGRATION WITH AI AND ML 58 5.3.3 INTEGRATION WITH WEARABLE DEVICES 58 5.4 TECHNOLOGY ANALYSIS 59 5.4.1 KEY TECHNOLOGIES 59 5.4.1.1 Wireless communication systems 59 5.4.1.2 Sensor technologies 59 5.4.1.3 Self-powered ingestible smart pills 60 5.4.1.4 Adaptive frame rate technologies 60 5.4.1.5 iMAG 61 5.4.1.6 AI and ML 62 5.4.2 COMPLEMENTARY TECHNOLOGIES 62 5.4.2.1 Robotic technologies 62 5.4.2.2 Data analytics 63 5.4.3 ADJACENT TECHNOLOGIES 63 5.4.3.1 IoT 63 5.4.3.2 Cloud computing 63 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63 5.6 PIPELINE ANALYSIS 64 5.7 PORTER’S FIVE FORCES ANALYSIS 66 5.7.1 INTENSITY OF COMPETITIVE RIVALRY 67 5.7.2 THREAT OF NEW ENTRANTS 67 5.7.3 THREAT OF SUBSTITUTES 68 5.7.4 BARGAINING POWER OF SUPPLIERS 68 5.7.5 BARGAINING POWER OF BUYERS 68 5.8 KEY STAKEHOLDERS & BUYING CRITERIA 69 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 69 5.8.2 KEY BUYING CRITERIA 69 5.9 ECOSYSTEM ANALYSIS 70 5.10 VALUE CHAIN ANALYSIS 71 5.11 TARIFF & REGULATORY ANALYSIS 72 5.11.1 TARIFF DATA ANALYSIS 72 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.11.3 REGULATORY LANDSCAPE 74 5.11.3.1 North America 74 5.11.3.1.1 US 74 5.11.3.2 Europe 75 5.11.3.3 Asia Pacific 75 5.11.3.3.1 Japan 75 5.11.3.3.2 China 76 5.11.3.3.3 India 77 5.12 PRICING ANALYSIS 78 5.12.1 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023 78 5.12.2 AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020–2023 79 5.13 CASE STUDY ANALYSIS 79 5.13.1 INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES 79 5.13.2 DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES 80 5.13.3 AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS 80 5.14 PATENT ANALYSIS 81 5.14.1 PATENT PUBLICATION TRENDS FOR SMART PILLS 81 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 82 5.14.3 LIST OF KEY PATENTS 83 5.15 KEY CONFERENCES & EVENTS, 2025–2026 84 5.16 UNMET NEEDS & END-USER EXPECTATIONS 85 5.16.1 UNMET NEEDS 85 5.16.2 END-USER EXPECTATIONS 86 5.17 TRADE ANALYSIS 87 5.18 INVESTMENT & FUNDING SCENARIO 88 5.19 BUSINESS MODEL ANALYSIS 88 5.19.1 DIRECT SALES TO HEALTHCARE PROVIDERS 88 5.19.2 SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES 88 5.20 IMPACT OF AI/GEN AI ON SMART PILLS MARKET 88 5.20.1 KEY USE CASES 90 5.20.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION 90 5.20.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding 90 5.20.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors 91 5.20.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92 5.20.3.1 AI in endoscopy 92 5.20.3.2 Wearable devices 92 5.20.3.3 Digital healthcare 93 5.20.3.4 Home healthcare 93 5.20.4 USER READINESS & IMPACT ASSESSMENT 93 5.20.4.1 User readiness 93 5.20.4.1.1 User A: Hospitals 93 5.20.4.1.2 User B: Diagnostic centers 93 5.20.4.2 Impact assessment 94 5.20.4.2.1 User A: Hospitals 94 5.20.4.2.1.1 Implementation 94 5.20.4.2.1.2 Impact 94 5.20.4.2.2 User B: Diagnostic centers 94 5.20.4.2.2.1 Implementation 94 5.20.4.2.2.2 Impact 95 6 SMART PILLS MARKET, BY TARGET AREA 96 6.1 INTRODUCTION 97 6.2 SMALL INTESTINE 97 6.2.1 COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE TO AID ADOPTION OF SMART PILLS 97 6.3 LARGE INTESTINE 98 6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH 98 6.4 ESOPHAGUS 99 6.4.1 HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT’S ESOPHAGUS TO AUGMENT MARKET GROWTH 99 6.5 STOMACH 100 6.5.1 IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET 100 7 SMART PILLS MARKET, BY APPLICATION 102 7.1 INTRODUCTION 103 7.2 CAPSULE ENDOSCOPY 103 7.2.1 INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET 103 7.3 PATIENT MONITORING 105 7.3.1 NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET 105 7.4 TARGETED DRUG DELIVERY 106 7.4.1 SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE AND REDUCE HEALTHCARE COSTS 106 8 SMART PILLS MARKET, BY DISEASE INDICATION 108 8.1 INTRODUCTION 109 8.2 OCCULT GASTROINTESTINAL BLEEDING 109 8.2.1 IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE 109 8.3 CROHN’S DISEASE 110 8.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS 110 8.4 CELIAC DISEASE 111 8.4.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET 111 8.5 SMALL BOWEL TUMORS 112 8.5.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH 112 8.6 OTHER DISEASE INDICATIONS 112 9 SMART PILLS MARKET, BY END USER 114 9.1 INTRODUCTION 115 9.2 HOSPITALS 115 9.2.1 INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS 115 9.3 DIAGNOSTIC CENTERS 116 9.3.1 BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH 116 9.4 OUTPATIENT SETTINGS 117 9.4.1 NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE TO SPUR MARKET GROWTH 117 9.5 OTHER END USERS 118 10 SMART PILLS MARKET, BY REGION 120 10.1 INTRODUCTION 121 10.2 NORTH AMERICA 122 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 123 10.2.2 US 125 10.2.2.1 US to dominate North American smart pills market during study period 125 10.2.3 CANADA 128 10.2.3.1 Rising incidence of IBD among geriatric population to propel market growth 128 10.3 EUROPE 130 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130 10.3.2 GERMANY 132 10.3.2.1 Rising prevalence of Crohn’s disease to aid market growth 132 10.3.3 UK 134 10.3.3.1 Increasing prevalence of bowel cancer and colitis to augment market growth 134 10.3.4 FRANCE 136 10.3.4.1 Favorable reimbursement coverage by government and third-party payers to aid market growth 136 10.3.5 ITALY 138 10.3.5.1 Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth 138 10.3.6 SPAIN 140 10.3.6.1 Rising demand for non-invasive diagnostics to fuel uptake of smart pills 140 10.3.7 REST OF EUROPE 142 10.4 ASIA PACIFIC 144 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 145 10.4.2 JAPAN 147 10.4.2.1 Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market 147 10.4.3 CHINA 150 10.4.3.1 Increasing geriatric population and rising incidence of gastric cancer to boost market growth 150 10.4.4 INDIA 152 10.4.4.1 Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth 152 10.4.5 REST OF ASIA PACIFIC 154 10.5 LATIN AMERICA 156 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 157 10.5.2 BRAZIL 159 10.5.2.1 Favorable government policies and presence of universal health coverage to aid market growth 159 10.5.3 MEXICO 161 10.5.3.1 Increased cancer awareness and favorable government initiatives to drive market 161 10.5.4 REST OF LATIN AMERICA 163 10.6 MIDDLE EAST & AFRICA 164 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 165 10.6.2 GCC COUNTRIES 167 10.6.2.1 Increased focus on healthcare infrastructure development and high R&D investment to support market growth 167 10.6.3 REST OF MIDDLE EAST & AFRICA 168 11 COMPETITIVE LANDSCAPE 171 11.1 INTRODUCTION 171 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 171 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SMART PILLS MARKET 171 11.3 REVENUE ANALYSIS, 2019–2023 174 11.4 MARKET SHARE ANALYSIS, 2023 175 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 176 11.5.1 STARS 176 11.5.2 EMERGING LEADERS 176 11.5.3 PERVASIVE PLAYERS 176 11.5.4 PARTICIPANTS 176 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 178 11.5.5.1 Company footprint 178 11.5.5.2 Region footprint 179 11.5.5.3 Application footprint 180 11.5.5.4 Target area footprint 181 11.5.5.5 Disease indication footprint 181 11.5.5.6 End-user footprint 182 11.5.5.7 Region footprint 183 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 183 11.6.1 PROGRESSIVE COMPANIES 183 11.6.2 RESPONSIVE COMPANIES 183 11.6.3 DYNAMIC COMPANIES 183 11.6.4 STARTING BLOCKS 184 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 185 11.6.5.1 Detailed list of key startups/SME players 185 11.6.5.2 Competitive benchmarking of key startups/SME players 186 11.7 COMPANY VALUATION & FINANCIAL METRICS 187 11.7.1 FINANCIAL METRICS 187 11.7.2 COMPANY VALUATION 187 11.8 BRAND/PRODUCT COMPARISON 188 11.9 COMPETITIVE SCENARIO 189 11.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS 189 11.9.2 DEALS 190 11.9.3 OTHER DEVELOPMENTS 191 12 COMPANY PROFILES 192 12.1 KEY PLAYERS 192 12.1.1 MEDTRONIC 192 12.1.1.1 Business overview 192 12.1.1.2 Products/Services/Solutions offered 193 12.1.1.3 Recent developments 194 12.1.1.3.1 Product approvals & enhancements 194 12.1.1.3.2 Deals 194 12.1.1.4 MnM view 195 12.1.1.4.1 Right to win 195 12.1.1.4.2 Strategic choices 195 12.1.1.4.3 Weaknesses & competitive threats 195 12.1.2 OLYMPUS CORPORATION 196 12.1.2.1 Business overview 196 12.1.2.2 Products/Services/Solutions offered 197 12.1.2.3 Recent developments 198 12.1.2.3.1 Other developments 198 12.1.2.4 MnM view 198 12.1.2.4.1 Right to win 198 12.1.2.4.2 Strategic choices 198 12.1.2.4.3 Weaknesses & competitive threats 198 12.1.3 CAPSOVISION, INC. 199 12.1.3.1 Business overview 199 12.1.3.2 Products/Services/Solutions offered 199 12.1.3.3 Recent developments 200 12.1.3.3.1 Product approvals & enhancements 200 12.1.3.4 MnM view 201 12.1.3.4.1 Right to win 201 12.1.3.4.2 Strategic choices 201 12.1.3.4.3 Weaknesses & competitive threats 201 12.1.4 INTROMEDIC 202 12.1.4.1 Business overview 202 12.1.4.2 Products/Services/Solutions offered 202 12.1.4.3 MnM view 203 12.1.4.3.1 Right to win 203 12.1.4.3.2 Strategic choices 203 12.1.4.3.3 Weaknesses & competitive threats 203 12.1.5 JINSHAN SCIENCE & TECHNOLOGY 204 12.1.5.1 Business overview 204 12.1.5.2 Products/Services/Solutions offered 204 12.1.5.3 MnM view 205 12.1.5.3.1 Right to win 205 12.1.5.3.2 Strategic choices 205 12.1.5.3.3 Weaknesses & competitive threats 205 12.1.6 ANX ROBOTICS 206 12.1.6.1 Business overview 206 12.1.6.2 Products/Services/Solutions offered 206 12.1.6.3 Recent developments 207 12.1.6.3.1 Product launches, approvals, and enhancements 207 12.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD. 208 12.1.7.1 Business overview 208 12.1.7.2 Products/Services/Solutions offered 208 12.1.8 ETECTRX 209 12.1.8.1 Business overview 209 12.1.8.2 Products/Services/Solutions offered 209 12.1.8.3 Recent developments 210 12.1.8.3.1 Product enhancements 210 12.1.8.3.2 Deals 210 12.1.9 BODYCAP 211 12.1.9.1 Business overview 211 12.1.9.2 Products/Services/Solutions offered 211 12.1.9.3 Recent developments 212 12.1.9.3.1 Product launches 212 12.1.9.3.2 Deals 212 12.1.10 CHECK-CAP 213 12.1.10.1 Business overview 213 12.1.10.2 Products/Services/Solutions offered 213 12.1.10.3 Recent developments 214 12.1.10.3.1 Product approvals 214 12.1.10.3.2 Expansions 214 12.1.11 SHANGXIAN MINIMAL INVASIVE INC. 215 12.1.11.1 Business overview 215 12.1.11.2 Products/Services/Solutions offered 215 12.2 OTHER PLAYERS 216 12.2.1 VELOCE CORPORATION 216 12.2.2 BIOCAM 216 12.2.3 ENDIATX 217 12.2.4 RF CO., LTD. 217 12.2.5 CELERO SYSTEMS 218 12.2.6 BIORA THERAPEUTICS, INC. 218 12.2.7 INNURVATION 219 12.2.8 RANI THERAPEUTICS 220 12.2.9 MOTILIS MEDICA SA 221 13 APPENDIX 222 13.1 DISCUSSION GUIDE 222 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 226 13.3 CUSTOMIZATION OPTIONS 228 13.4 RELATED REPORTS 228 13.5 AUTHOR DETAILS 229

圖表清單 List of Tables & Figures

TABLE 1 SMART PILLS MARKET: INCLUSIONS & EXCLUSIONS 27 TABLE 2 SMART PILLS MARKET: STUDY ASSUMPTIONS 41 TABLE 3 SMART PILLS MARKET: RISK ANALYSIS 41 TABLE 4 SMART PILLS MARKET: IMPACT ANALYSIS 52 TABLE 5 SENSOR AND BATTERY TYPES FOR CAPSULE ENDOSCOPY PRODUCTS 61 TABLE 6 SENSORS USED FOR VITAL SIGN MONITORING PRODUCTS 62 TABLE 7 SMART PILLS MARKET: DRUGS UNDER PIPELINE 64 TABLE 8 SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS 66 TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%) 69 TABLE 10 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 70 TABLE 11 TARIFF DATA FOR HS CODE 901890 72 TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 15 US FDA: MEDICAL DEVICE CLASSIFICATION 74 TABLE 16 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 74 TABLE 17 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75 TABLE 18 JAPAN: MEDICAL DEVICES CLASSIFICATION UNDER PMDA 76 TABLE 19 CHINA: CLASSIFICATION UNDER CLASS I/II/III MEDICAL DEVICES 76 TABLE 20 INDIA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77 TABLE 21 AVERAGE SELLING PRICE OF CAPSULE ENDOSCOPES, BY KEY PLAYER, 2023 (USD) 78 TABLE 22 AVERAGE SELLING PRICE TREND OF CAPSULE ENDOSCOPES, BY REGION, 2020–2023 (USD PER UNIT) 79 TABLE 23 CASE STUDY 1: INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES 79 TABLE 24 CASE STUDY 2: DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES 80 TABLE 25 CASE STUDY 3: AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS 80 TABLE 26 SMART PILLS MARKET: LIST OF KEY PATENTS, JANUARY 2020–DECEMBER 2024 83 TABLE 27 SMART PILLS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 84 TABLE 28 SMART PILLS MARKET: UNMET NEEDS 85 TABLE 29 SMART PILLS MARKET: END-USER EXPECTATIONS 86 TABLE 30 TOP 10 IMPORTERS FOR HSN CODE 901890, BY COUNTRY, 2020−2023 (USD THOUSAND) 87 TABLE 31 TOP 10 EXPORTERS FOR HSN CODE 901890, BY COUNTRY, 2020−2023 (USD THOUSAND) 87 TABLE 32 CASE STUDY 1: CAPSOCAM SV-1 VERSUS PILLCAM SB3 TO DETECT OBSCURE GASTROINTESTINAL BLEEDING 90 TABLE 33 CASE STUDY 2: AARDEX GROUP PARTNERED WITH ETECTRX, INC. TO TRACK MEDICATION-TAKING BEHAVIORS 91 TABLE 34 SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 97 TABLE 35 SMART PILLS MARKET FOR SMALL INTESTINE, BY REGION, 2022–2030 (USD MILLION) 98 TABLE 36 SMART PILLS MARKET FOR LARGE INTESTINE, BY REGION, 2022–2030 (USD MILLION) 99 TABLE 37 SMART PILLS MARKET FOR ESOPHAGUS, BY REGION, 2022–2030 (USD MILLION) 100 TABLE 38 SMART PILLS MARKET FOR STOMACH, BY REGION, 2022–2030 (USD MILLION) 101 TABLE 39 SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 103 TABLE 40 KEY CAPSULE ENDOSCOPES OFFERED BY MAJOR MARKET PLAYERS 104 TABLE 41 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION, 2022–2030 (USD MILLION) 104 TABLE 42 KEY PATIENT MONITORING SMART PILLS OFFERED BY MAJOR MARKET PLAYERS 105 TABLE 43 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION, 2022–2030 (USD MILLION) 106 TABLE 44 KEY TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE 107 TABLE 45 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY REGION, 2022–2030 (USD MILLION) 107 TABLE 46 SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 109 TABLE 47 SMART PILLS MARKET FOR OCCULT GASTROINTESTINAL BLEEDING, BY REGION, 2022–2030 (USD MILLION) 110 TABLE 48 SMART PILLS MARKET FOR CROHN’S DISEASE, BY REGION, 2022–2030 (USD MILLION) 111 TABLE 49 SMART PILLS MARKET FOR CELIAC DISEASE, BY REGION, 2022–2030 (USD MILLION) 111 TABLE 50 SMART PILLS MARKET FOR SMALL BOWEL TUMORS, BY REGION, 2022–2030 (USD MILLION) 112 TABLE 51 SMART PILLS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022–2030 (USD MILLION) 113 TABLE 52 SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 115 TABLE 53 SMART PILLS MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION) 116 TABLE 54 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022–2030 (USD MILLION) 117 TABLE 55 SMART PILLS MARKET FOR OUTPATIENT SETTINGS, BY REGION, 2022–2030 (USD MILLION) 118 TABLE 56 SMART PILLS MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION) 119 TABLE 57 SMART PILLS MARKET, BY REGION, 2022–2030 (USD MILLION) 121 TABLE 58 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION, 2022–2030 (THOUSAND UNITS) 121 TABLE 59 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION, 2022–2030 (THOUSAND UNITS) 122 TABLE 60 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 124 TABLE 61 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 124 TABLE 62 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 124 TABLE 63 NORTH AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 125 TABLE 64 NORTH AMERICA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 125 TABLE 65 US: KEY MACROINDICATORS 126 TABLE 66 US: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 127 TABLE 67 US: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 127 TABLE 68 US: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 127 TABLE 69 US: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 128 TABLE 70 CANADA: KEY MACROINDICATORS 128 TABLE 71 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 129 TABLE 72 CANADA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 129 TABLE 73 CANADA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 129 TABLE 74 CANADA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 130 TABLE 75 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131 TABLE 76 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 131 TABLE 77 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 131 TABLE 78 EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 132 TABLE 79 EUROPE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 132 TABLE 80 GERMANY: KEY MACROINDICATORS 133 TABLE 81 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 133 TABLE 82 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 133 TABLE 83 GERMANY: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 134 TABLE 84 GERMANY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 134 TABLE 85 UK: KEY MACROINDICATORS 135 TABLE 86 UK: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 135 TABLE 87 UK: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 135 TABLE 88 UK: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 136 TABLE 89 UK: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 136 TABLE 90 FRANCE: KEY MACROINDICATORS 137 TABLE 91 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 137 TABLE 92 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 137 TABLE 93 FRANCE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 138 TABLE 94 FRANCE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 138 TABLE 95 ITALY: KEY MACROINDICATORS 139 TABLE 96 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 139 TABLE 97 ITALY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 139 TABLE 98 ITALY: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 140 TABLE 99 ITALY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 140 TABLE 100 SPAIN: KEY MACROINDICATORS 141 TABLE 101 SPAIN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 141 TABLE 102 SPAIN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 141 TABLE 103 SPAIN: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 142 TABLE 104 SPAIN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 142 TABLE 105 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 143 TABLE 106 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 143 TABLE 107 REST OF EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 143 TABLE 108 REST OF EUROPE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 144 TABLE 109 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 110 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 146 TABLE 111 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 146 TABLE 112 ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 147 TABLE 113 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 147 TABLE 114 JAPAN: KEY MACROINDICATORS 148 TABLE 115 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 148 TABLE 116 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 149 TABLE 117 JAPAN: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 149 TABLE 118 JAPAN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 149 TABLE 119 CHINA: KEY MACROINDICATORS 150 TABLE 120 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 151 TABLE 121 CHINA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 151 TABLE 122 CHINA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 151 TABLE 123 CHINA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 152 TABLE 124 INDIA: KEY MACROINDICATORS 153 TABLE 125 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 153 TABLE 126 INDIA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 153 TABLE 127 INDIA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 154 TABLE 128 INDIA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 154 TABLE 129 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 155 TABLE 130 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 155 TABLE 131 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 156 TABLE 132 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 156 TABLE 133 LATIN AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157 TABLE 134 LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 157 TABLE 135 LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 158 TABLE 136 LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 158 TABLE 137 LATIN AMERICA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 158 TABLE 138 BRAZIL: KEY MACROINDICATORS 159 TABLE 139 BRAZIL: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 159 TABLE 140 BRAZIL: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 160 TABLE 141 BRAZIL: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 160 TABLE 142 BRAZIL: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 160 TABLE 143 MEXICO: KEY MACROINDICATORS 161 TABLE 144 MEXICO: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 161 TABLE 145 MEXICO: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 162 TABLE 146 MEXICO: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 162 TABLE 147 MEXICO: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 162 TABLE 148 REST OF LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 163 TABLE 149 REST OF LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 163 TABLE 150 REST OF LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 164 TABLE 151 REST OF LATIN AMERICA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 164 TABLE 152 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY REGION, 2022–2030 (USD MILLION) 165 TABLE 153 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 165 TABLE 154 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 166 TABLE 155 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 166 TABLE 156 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 166 TABLE 157 GCC COUNTRIES: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 167 TABLE 158 GCC COUNTRIES: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 167 TABLE 159 GCC COUNTRIES: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 168 TABLE 160 GCC COUNTRIES: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 168 TABLE 161 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 169 TABLE 162 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 169 TABLE 163 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 169 TABLE 164 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 170 TABLE 165 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SMART PILLS MARKET, JANUARY 2021–JANUARY 2025 171 TABLE 166 SMART PILLS MARKET: DEGREE OF COMPETITION 175 TABLE 167 SMART PILLS MARKET: REGION FOOTPRINT 179 TABLE 168 SMART PILLS MARKET: APPLICATION FOOTPRINT 180 TABLE 169 SMART PILLS MARKET: TARGET AREA FOOTPRINT 181 TABLE 170 SMART PILLS MARKET: DISEASE INDICATION FOOTPRINT 181 TABLE 171 SMART PILLS MARKET: END-USER FOOTPRINT 182 TABLE 172 SMART PILLS MARKET: REGION FOOTPRINT 183 TABLE 173 SMART PILLS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 185 TABLE 174 SMART PILLS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 186 TABLE 175 SMART PILLS MARKET: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025 189 TABLE 176 SMART PILLS MARKET: DEALS, JANUARY 2021–JANUARY 2025 190 TABLE 177 SMART PILLS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 191 TABLE 178 MEDTRONIC: COMPANY OVERVIEW 192 TABLE 179 MEDTRONIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 193 TABLE 180 MEDTRONIC: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025 194 TABLE 181 MEDTRONIC: DEALS, JANUARY 2021–JANUARY 2025 194 TABLE 182 OLYMPUS CORPORATION: COMPANY OVERVIEW 196 TABLE 183 OLYMPUS CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 197 TABLE 184 OLYMPUS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 198 TABLE 185 CAPSOVISION, INC.: COMPANY OVERVIEW 199 TABLE 186 CAPSOVISION, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 199 TABLE 187 CAPSOVISION, INC.: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025 200 TABLE 188 INTROMEDIC: COMPANY OVERVIEW 202 TABLE 189 INTROMEDIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 202 TABLE 190 JINSHAN SCIENCE & TECHNOLOGY: COMPANY OVERVIEW 204 TABLE 191 JINSHAN SCIENCE & TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 204 TABLE 192 ANX ROBOTICS: COMPANY OVERVIEW 206 TABLE 193 ANX ROBOTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 206 TABLE 194 ANX ROBOTICS: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025 207 TABLE 195 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 208 TABLE 196 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS/SERVICES/ SOLUTIONS OFFERED 208 TABLE 197 ETECTRX: COMPANY OVERVIEW 209 TABLE 198 ETECTRX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 209 TABLE 199 ETECTRX: PRODUCT ENHANCEMENTS, JANUARY 2021–JANUARY 2025 210 TABLE 200 ETECTRX: DEALS, JANUARY 2021–JANUARY 2025 210 TABLE 201 BODYCAP: COMPANY OVERVIEW 211 TABLE 202 BODYCAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 211 TABLE 203 BODYCAP: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025 212 TABLE 204 BODYCAP: DEALS, JANUARY 2021–JANUARY 2025 212 TABLE 205 CHECK-CAP: COMPANY OVERVIEW 213 TABLE 206 CHECK-CAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 213 TABLE 207 CHECK-CAP: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 214 TABLE 208 CHECK-CAP: EXPANSIONS, JANUARY 2021–JANUARY 2025 214 TABLE 209 SHANGXIAN MINIMAL INVASIVE INC.: COMPANY OVERVIEW 215 TABLE 210 SHANGXIAN MINIMAL INVASIVE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 215 TABLE 211 VELOCE CORPORATION: COMPANY OVERVIEW 216 TABLE 212 BIOCAM: COMPANY OVERVIEW 216 TABLE 213 ENDIATX: COMPANY OVERVIEW 217 TABLE 214 RF CO., LTD.: COMPANY OVERVIEW 217 TABLE 215 CELERO SYSTEMS: COMPANY OVERVIEW 218 TABLE 216 BIORA THERAPEUTICS, INC.: COMPANY OVERVIEW 218 TABLE 217 INNURVATION: COMPANY OVERVIEW 219 TABLE 218 RANI THERAPEUTICS: COMPANY OVERVIEW 220 TABLE 219 MOTILIS MEDICA SA: COMPANY OVERVIEW 221 _ _ FIGURE 1 SMART PILLS MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 26 FIGURE 2 SMART PILLS MARKET: YEARS CONSIDERED 28 FIGURE 3 SMART PILLS MARKET: RESEARCH DESIGN 30 FIGURE 4 SMART PILLS MARKET: KEY DATA FROM SECONDARY SOURCES 31 FIGURE 5 SMART PILLS MARKET: KEY PRIMARY SOURCES 32 FIGURE 6 SMART PILLS MARKET: KEY DATA FROM PRIMARY SOURCES 33 FIGURE 7 SMART PILLS MARKET: INSIGHTS FROM KEY PRIMARIES 33 FIGURE 8 BREAKDOWN OF PRIMARY EXPERTS: BY COMPANY TYPE, DESIGNATION, AND REGION 34 FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 35 FIGURE 10 SMART PILLS MARKET: BOTTOM-UP APPROACH (DEMAND-SIDE ANALYSIS) 36 FIGURE 11 SMART PILLS MARKET: TOP-DOWN APPROACH 36 FIGURE 12 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030) 38 FIGURE 13 SMART PILLS MARKET: CAGR PROJECTIONS (SUPPLY SIDE) 38 FIGURE 14 SMART PILLS MARKET: DATA TRIANGULATION 40 FIGURE 15 SMART PILLS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 43 FIGURE 16 SMART PILLS MARKET, BY TARGET AREA, 2024 VS. 2030 (USD MILLION) 44 FIGURE 17 SMART PILLS MARKET, BY DISEASE INDICATION, 2024 VS. 2030 (USD MILLION) 44 FIGURE 18 SMART PILLS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 45 FIGURE 19 REGIONAL SNAPSHOT OF SMART PILLS MARKET 45 FIGURE 20 INCREASING ADOPTION OF CAPSULE ENDOSCOPY IN EMERGING ECONOMIES TO FUEL UPTAKE OF SMART PILLS 47 FIGURE 21 US AND CAPSULE ENDOSCOPY SEGMENTS DOMINATED NORTH AMERICAN SMART PILLS MARKET IN 2023 48 FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 49 FIGURE 23 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 49 FIGURE 24 EMERGING MARKETS TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 50 FIGURE 25 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 26 HEALTHCARE SECURITY BREACHES OF 500 + RECORDS, 2009–2024 57 FIGURE 27 SMART PILLS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63 FIGURE 28 SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS 67 FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION 69 FIGURE 30 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 69 FIGURE 31 SMART PILLS MARKET: ECOSYSTEM ANALYSIS 70 FIGURE 32 SMART PILLS MARKET: VALUE CHAIN ANALYSIS 71 FIGURE 33 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER (2023) 78 FIGURE 34 SMART PILLS MARKET: GLOBAL PATENT PUBLICATION TRENDS (2015–2024) 81 FIGURE 35 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILL PATENTS (JANUARY 2014–DECEMBER 2024) 82 FIGURE 36 TOP APPLICANTS FOR SMART PILL PATENTS (COUNTRY/REGION) (JANUARY 2014–DECEMBER 2024) 83 FIGURE 37 SMART PILLS MARKET: FUNDING AND NUMBER OF DEALS (2020–2024) 88 FIGURE 38 MARKET POTENTIAL OF AI/GEN AI ON SMART PILLS ACROSS INDUSTRIES 89 FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92 FIGURE 40 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT 123 FIGURE 41 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT 145 FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET, 2019–2023 (USD MILLION) 174 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET (2023) 175 FIGURE 44 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 177 FIGURE 45 SMART PILLS MARKET: COMPANY FOOTPRINT 178 FIGURE 46 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 184 FIGURE 47 EV/EBITDA OF KEY VENDORS 187 FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 187 FIGURE 49 SMART PILLS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 188 FIGURE 50 MEDTRONIC: COMPANY SNAPSHOT 193 FIGURE 51 OLYMPUS CORPORATION: COMPANY SNAPSHOT 197

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

Smart Pills Market by Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring), Target Area (Esophagus, Small Intestine, Large Intestine, Stomach), End User (Hospitals, Diagnostic Centers), and Region - Global Forecast to 2030

授權報價

報告摘要

同分類最新報告（醫療器材）